利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.022 秒)

    Method of detecting relative risk for the onset of atopic dermatitis by gene single nucleotide polymorphism analysis
    1.
    发明授权
    Method of detecting relative risk for the onset of atopic dermatitis by gene single nucleotide polymorphism analysis 失效
    通过基因单核苷酸多态性分析检测特应性皮炎发病相对危险度的方法

    公开(公告)号：US08071307B2

    公开(公告)日：2011-12-06

    申请号：US11887769

    申请日：2006-04-03

    申请人： Keiko Tanaka ,  Julian M. Hopkin

    发明人： Keiko Tanaka ,  Julian M. Hopkin

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/156

    摘要： The present invention provides a method of discriminating a relative risk for the morbidity of atopic dermatitis of a test subject comprising: analyzing gene polymorphism of two or more of genes related to onset of atopic dermatitis using a sample isolated from a statistically significant number of normal persons and patients of atopic dermatitis to determine relative ratios (percentages (%)) related to the individual gene polymorphism of individual derived from the analysis; and calculating an odds ratio according to specified gene polymorphism from the relative ratio; and using, as a discrimination criterion, a combination of two or more of gene polymorphisms showing a synergetically higher odds ratio than odds ratios according to individual gene polymorphism. The method is useful for predicting susceptibility of an AD patient to chemicals based on genes and for selecting the diagnostic and/or therapeutic agent by eliminating harmful drug reactions from the analysis of principal factors related to onset and development of AD and interaction among these genes, and for determining a diagnostic method and therapeutic method using the detection method of morbidity risk.

    摘要翻译： 本发明提供了一种鉴别测试对象特应性皮炎发病率的相对风险的方法，包括：使用从统计学上显着数量的正常人分离的样品分析与特应性皮炎发作相关的两个或多个基因的基因多态性 和特应性皮炎患者确定与分析得出的个体个体基因多态性相关的相对比例（百分比（％））; 并根据相对比例根据规定的基因多态性计算优势比; 并且根据个体基因多态性，使用两种或更多种基因多态性的组合，其显示出比优势比的协同优势比值比。 该方法可用于预测基于基因的AD患者对化学物质的敏感性，并且通过从与AD发生和发展以及这些基因之间的相互作用相关的主要因素的分析中消除有害药物反应来选择诊断和/或治疗剂， 并用于确定使用发病风险检测方法的诊断方法和治疗方法。

    LIQUID PREPARATION
    3.
    发明申请
    LIQUID PREPARATION 审中-公开
    液体制剂

    公开(公告)号：US20100004267A1

    公开(公告)日：2010-01-07

    申请号：US12375127

    申请日：2007-07-31

    申请人： Hiroo Kawamura ,  Tetsu Ono

    发明人： Hiroo Kawamura ,  Tetsu Ono

    IPC分类号： A61K31/4965 ,  A61P9/10

    CPC分类号： A61K9/0019 ,  A61K9/08 ,  A61K31/495 ,  A61K47/183 ,  A61K47/20 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00

    摘要： It is provided a liquid preparation stably including (2S)-1-(4-amino-2,3,5-trimethylphenoxy)-3-{4-[4-(4-fluorobenzyl)phenyl]-1-piperazinyl}-2-propanol or its pharmaceutically acceptable salt as an active ingredient.The present invention relates to a liquid preparation including the above compound or its pharmaceutically acceptable salt as an active ingredient, the liquid preparation including: (a) at least one selected from the group consisting of sulfite, bisulfite, pyrosulfite, α-thioglycerol and cysteine, (b) a β-cyclodextrin derivative, and (c) a pH buffer, wherein the pH value thereof is adjusted within a range of from 3 to 5.

    摘要翻译： 提供稳定的液体制剂，其包含（2S）-1-（4-氨基-2,3,5-三甲基苯氧基）-3- {4- [4-（4-氟苄基）苯基] -1-哌嗪基} -2 丙醇或其药学上可接受的盐作为活性成分。 本发明涉及包含上述化合物或其药学上可接受的盐作为活性成分的液体制剂，该液体制剂包括：（a）选自亚硫酸盐，亚硫酸氢盐，焦亚硫酸盐，α-硫代甘油和半胱氨酸中的至少一种 ，（b）β-环糊精衍生物，和（c）pH缓冲剂，其pH值调节在3〜5的范围内。

    METHOD FOR PURIFYING CARDIOMYOCYTES OR PROGRAMMED CARDIOMYOCYTES DERIVED FROM STEM CELLS OR FETUSES
    4.
    发明申请
    METHOD FOR PURIFYING CARDIOMYOCYTES OR PROGRAMMED CARDIOMYOCYTES DERIVED FROM STEM CELLS OR FETUSES 有权
    净化心肌细胞或从干细胞衍生的编程性心肌细胞的方法

    公开(公告)号：US20090275132A1

    公开(公告)日：2009-11-05

    申请号：US12162684

    申请日：2007-01-31

    申请人： Fumiyuki Hattori ,  Keiichi Fukuda

    发明人： Fumiyuki Hattori ,  Keiichi Fukuda

    IPC分类号： C12N5/06

    CPC分类号： C12N5/0657 ,  C12N2500/02 ,  C12N2500/14 ,  C12N2500/25 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2500/90 ,  C12N2500/99 ,  C12N2501/115 ,  C12N2501/235 ,  C12N2501/70 ,  C12N2506/02

    摘要： An object of the present invention is to develop a method for purify cardiomyocytes at a high degree of purification and at a high yield from a cell mixture comprising cardiomyocytes derived from fetuses and stem cells using various features which have not been previously expected to be used for purification of cardiomyocytes or which are newly found, wherein said method is carried out without undergoing any genetic modification or without adding any special proteins or biologically active agents.The inventors of the present invention found that cardiomyocytes were effectively and highly selected and purified by culturing cardiomyocytes derived from embryonic stem cells in the culture medium under a condition selected from a low-serum-supplemented condition, a low-glucose-supplemented condition, a low-nutritional condition, a low calcium condition, a mildly-acidic pH condition, a lactic acid-supplemented condition, an aspartic acid/glutamic acid-supplemented condition, and/or a pyruvic acid-supplemented condition. The inventors of the present invention further found that the above method invented in relation to embryonic stem cells was applicable to select and purify cardiomyocytes derived from fetuses or adult stem cells.

    摘要翻译： 本发明的一个目的是开发一种以高度纯化和高产率从包含来自胎儿和干细胞的心肌细胞的细胞混合物中纯化心肌细胞的方法，该方法使用先前预期不会用于 纯化心肌细胞或新发现的，其中所述方法进行而不经历任何遗传修饰或不添加任何特殊的蛋白质或生物活性剂。 本发明人发现，通过在选自低血清补充条件，低葡萄糖补充条件，细菌培养条件下的培养基中培养来源于培养基中的胚胎干细胞的心肌细胞，有效地和高度地选择和纯化心肌细胞 低营养状态，低钙状态，轻度酸性pH条件，补充乳酸的条件，天冬氨酸/谷氨酸补充条件和/或丙酮酸补充条件。 本发明人进一步发现，关于胚胎干细胞发明的上述方法适用于选择和纯化来源于胎儿或成体干细胞的心肌细胞。

    Processes for preparation of organic compounds
    5.
    发明授权
    Processes for preparation of organic compounds 失效
    有机化合物的制备方法

    公开(公告)号：US07358356B2

    公开(公告)日：2008-04-15

    申请号：US10529392

    申请日：2003-10-02

    申请人： Mitsuru Takase ,  Takahiro Sagae ,  Hiroyuki Yazaki ,  Shigeo Mori ,  Daisuke Asanuma

    发明人： Mitsuru Takase ,  Takahiro Sagae ,  Hiroyuki Yazaki ,  Shigeo Mori ,  Daisuke Asanuma

    IPC分类号： C07D499/18

    CPC分类号： C07D499/893 ,  C07D499/88

    摘要： The present invention provides a method for preparing an organic compound, which comprises a dehydration step of distilling off water from a polar organic solvent solution containing the organic compound and water to bring the concentration of water below a given level, wherein the dehydration step comprises distilling off water together with the polar organic solvent while adding a polar organic solvent to the solution, or comprises repeating several cycles of adding a polar organic solvent to the solution and then distilling off water together with the polar organic solvent. The present invention further provides the preparation of an organic compound, which enables efficient isolation of the target product in high isolated yield from a polar organic solvent solution containing the organic compound, water and, if necessary, a compound which produces, upon coming into contact with water or the like, a substance accelerating the decomposition of the organic compound.

    摘要翻译： 本发明提供了一种制备有机化合物的方法，该方法包括从含有有机化合物和水的极性有机溶剂溶液中蒸馏出水以使水的浓度低于给定水平的脱水步骤，其中脱水步骤包括蒸馏 将极性有机溶剂与极性有机溶剂一起加入到溶液中，或者包括重复多次向溶液中加入极性有机溶剂，然后与极性有机溶剂一起蒸馏出水。 本发明还提供有机化合物的制备，其能够以高分离产率从含有有机化合物的极性有机溶剂溶液，水和必要时的化合物在接触时产生高分离产物。 用水等加速有机化合物分解的物质。

    Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
    6.
    发明申请
    Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof 审中-公开
    氨基苯氧基乙酰胺衍生物和含有它们的药物组合物

    公开(公告)号：US20060178401A1

    公开(公告)日：2006-08-10

    申请号：US11337664

    申请日：2006-01-24

    申请人： Naohiro Takemoto ,  Hirokazu Annoura ,  Norihito Murayama

    发明人： Naohiro Takemoto ,  Hirokazu Annoura ,  Norihito Murayama

    IPC分类号： A61K31/454 ,  A61K31/445 ,  C07D211/56 ,  C07D401/02

    CPC分类号： C07D417/04 ,  C07D211/58

    摘要： The present invention relates to an amiophenoxyacetamide derivative of the formula (I): wherein R1 to R4 are, independent from each other, a hydrogen atom or an optionally substituted alkyl group; E1 is —NR4—; and E2 is an oxygen atom or —NR10—; Q is the group —X—Y-Q′, wherein X and Y are connecting bonds or X is an alkylene or alkenylene group and Y is selected from a group comprising C═O, NHC(═O), and C(═O)NH, and Q′ is a hydrogen atom or a phenyl or pyridyl group which may be substituted; and pharmaceutically acceptable salts thereof. The present invention further relates to compositions comprising compounds of the formula (I) and methods of using said compounds for treating cerebral functional disorders and cerebral organic disorders.

    摘要翻译： 本发明涉及式（I）的氨基苯氧基乙酰胺衍生物：其中R 1至R 4彼此独立地为氢原子或任选取代的烷基 组; E 1是-NR 4 - ; 并且E 2是氧原子或-NR 10 - ; Q是-XY-Q'基团，其中X和Y是连接键或X是亚烷基或亚烯基，Y选自CO，NHC（-O）和C（-O）NH的基团，和 Q'是氢原子或可被取代的苯基或吡啶基; 及其药学上可接受的盐。 本发明还涉及包含式（I）化合物和使用所述化合物治疗脑功能障碍和脑部有机疾病的方法的组合物。

    Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors
    7.
    发明授权
    Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors 失效
    吡啶基吡唑并嘧啶酮衍生物作为PDE 7抑制剂

    公开(公告)号：US07943624B2

    公开(公告)日：2011-05-17

    申请号：US11748421

    申请日：2007-05-14

    申请人： Hidekazu Inoue ,  Hidenobu Murafuji ,  Yasuhiro Hayashi

    发明人： Hidekazu Inoue ,  Hidenobu Murafuji ,  Yasuhiro Hayashi

    IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P37/02 ,  A61P29/00

    CPC分类号： C07D487/04

    摘要： To provide the compounds inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is pyridinylpyrazolo-pyrimidinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl or cycloheptyl group, R2 is methyl; R3 is a group: —NR5R6 or —S(O)0-2R8;hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; and R4 is methoxy or ethoxy group.

    摘要翻译： 选择性地提供抑制PDE 7的化合物，从而提高细胞cAMP水平。 因此，该化合物可用于治疗各种疾病如过敏性疾病，炎性疾病或免疫疾病。 该化合物是下式（IA）或（IB）表示的吡啶基吡唑并嘧啶酮化合物：特别是R 1是环己基或环庚基，R 2是甲基; R3是基团：-NR5R6或-S（O）0-2R8;氢原子; 硝基; 氰基; 卤素原子; 杂芳基; R4为甲氧基或乙氧基。

    Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors
    8.
    发明授权
    Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors 失效
    咪唑并三嗪酮衍生物作为PDE 7（磷酸二酯酶7）抑制剂

    公开(公告)号：US07713972B2

    公开(公告)日：2010-05-11

    申请号：US10560503

    申请日：2004-06-11

    申请人： Hidekazu Inoue ,  Hidenobu Murafuji ,  Yasuhiro Hayashi

    发明人： Hidekazu Inoue ,  Hidenobu Murafuji ,  Yasuhiro Hayashi

    IPC分类号： A61K31/53 ,  A01N43/64 ,  A01N43/66 ,  C07D253/08 ,  C07D487/00

    CPC分类号： C07D487/04

    摘要： The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotriazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: —NR5R6, —C(O)R7, —SO2R7, —OR8, —NR8COR7, —NR8S02R7; A is CR4; and B is CH.

    摘要翻译： 本发明提供了选择性抑制PDE7的化合物，因此增强细胞cAMP水平。 因此，该化合物可用于治疗各种疾病如过敏性疾病，炎性疾病或免疫疾病。 该化合物是由下式（IA）或（IB）表示的咪唑并三氮酮化合物：特别是R 1是环己基，R 2是甲基; R3是氢原子; 硝基; 氰基; 卤素原子; 杂芳基; 取代或未取代的C 1 -C 6烷基; 取代或未取代的C 2 -C 6烯基; 取代或未取代的饱和或不饱和杂环烷基; 基团：-NR5R6，-C（O）R7，-SO2R7，-OR8，-NR8COR7，-NR8S02R7; A是CR4; 而B是CH。